Gianpaolo Marcacci
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"(IT)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Multiple Myeloma Research and Treatments, Peptidase Inhibition and Analysis, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia(2006)103 cited
- → Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma(2009)75 cited
- → Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy(2011)58 cited
- → Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study(2009)43 cited
- → Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study(2006)41 cited
- → Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma(2009)31 cited
- → Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials(2020)29 cited
- → High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study(2015)25 cited
- → DMSO-associated encephalopathy during autologous peripheral stem cell infusion: a predisposing role of preconditioning exposure to CNS-penetrating agents?(2009)22 cited
- → Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen(2015)19 cited